How much does a complete course of Erdafitinib cost?

Erdafitinib (Erdafitinib) is a targeted drug mainly used to treat advanced or metastatic bladder cancer related to FGFR gene mutations. The treatment regimen usually starts with a starting dose of 8 mg, which is taken orally once a day by the patient. Depending on tolerance, especially the occurrence of side effects such as phosphataemia, it may be increased to 9 mg once a day on days 14 to 21. The specific cost of this treatment option varies by market and region.

In the Chinese market, the price of the original drug of erdafitinib is relatively high, mainly the Hong Kong version of the original drug, and the monthly treatment cost is about 20,000 yuan. This price may pose a great financial pressure for some patients, especially in the case of long-term treatment.

However, foreign generic drugs are relatively affordable, especially those from countries such as Laos and Bangladesh. The price usually ranges from a few hundred to several thousand yuan, and the ingredients of these generic drugs are basically the same as those of the original drugs, so there is no significant difference in efficacy and safety. Although the price of generic drugs is lower, due to the wide variety of generic drugs on the market, patients need to ensure the reliability of their sources when choosing to avoid safety hazards caused by inferior drugs.

From the perspective of drug ingredients, the difference between original drugs and generic drugs is mainly reflected in the production process and price, while their therapeutic effects and side effects are roughly the same. When patients choose whether to use generic drugs, they should consider their own financial situation and the doctor's advice to ensure the rationality of the treatment plan.

In general, the treatment cost of erdafitinib varies greatly, and patients should comprehensively consider factors such as the source, price, and efficacy of the drug when choosing. With the development of the generic drug market, the financial burden on patients using erdafitinib may be reduced in the future, and it is also expected to increase the accessibility of this type of targeted drugs.

References：https://www.balversa.com/